氯前列醇钠 前列烯醇钠 氯前列烯醇钠CAS: 55028-72-3原料供应发货仅供科研实验
| 中文名 | 氯前列醇钠 |
| 英文名 | (+)-Cloprostenol Sodium |
| 别名 | 氯前列醇钠 前列烯醇钠 氯前列烯醇钠 氯前列腺素钠 氯比前列腺素钠 d-氯前列腺素钠 氯前列醇钠(D型) (±)-氯前列烯醇钠盐 7-[2-[4-(3-氯苯氧基)-3-羟基丁-1-烯基]-3,5-二羟基环戊基]庚-5-烯酸钠 (5Z)-7-[(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-氯苯氧基)-3-羟基-1-丁烯-1-基]-3,5-二羟基环戊基]-5-庚烯酸钠盐 |
| 英文别名 | 15(S)-CLOPROSTENOL Cloprostenol sodium 15-EPI CLOPROSTENOL D-Cloprostenol sodium DL-Cloprostenol sodiuM (+)-Cloprostenol Sodium (S)-CLOPROSTENOL SODIUM (5Z)-rel-Cloprostenol SodiuM (+)-16-M-CHLOROPHENOXY TETRANOR PROSTAGLANDIN F2ALPHA SODIUM SALT 7-(2-[4-(3-Chlorophenoxy)-3-hydroxy-1-butenyl]-3,5-dihydroxycyclopentyl)-5-heptenoic acid 16-(3-CHLOROPHENOXY)-9,11,15R-TRIHYDROXY-17,18,19,20-TETRANORPROSTA-5Z,13E-DIEN-1-OIC ACID SODIUM SALT sodium (5Z)-7-{(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl}hept-5-enoate (5Z)-7-[(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-Chlorophenoxy)-3-hydroxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-5-heptenoic acid sodium salt |
| CAS | 55028-72-3 62561-03-9 |
| EINECS | 259-439-3 |
| 化学式 | C22H28ClO6.Na |
| 分子量 | 446.9 |
| InChI | InChI=1/C22H29ClO6.Na/c23-15-6-5-7-17(12-15)29-14-16(24)10-11-19-18(20(25)13-21(19)26)8-3-1-2-4-9-22(27)28;/h1,3,5-7,10-12,16,18-21,24-26H,2,4,8-9,13-14H2,(H,27,28);/q;+1/p-1/b3-1-,11-10+;/t16-,18-,19-,20+,21-;/m1./s1 |
| InChIKey | IFEJLMHZNQJGQU-KXXGZHCCSA-M |
| 熔点 | 68-70°C |
| 沸点 | 628°C at 760 mmHg |
| 闪点 | 333.6°C |
| 蒸汽压 | 1.23E-16mmHg at 25°C |
| 溶解度 | H2O: >10 mg/mL |
| 存储条件 | Inert atmosphere,Store in freezer, under -20°C |
| 外观 | 固体 |
| 颜色 | light brown |
| 体外研究 | Cloprostenol is a PGF2α receptor agonist. Cloprostenol (0.1 μM) counteracts the adipogenic effects of statil, on both intracellular lipid accumulation and expression of transcripts for proadipogenic factors C/EBPα and PPARγ after treatment for 6 days. |
| 体内研究 | Cloprostenol sodium salt (25 μg) decreases plasma progesterone in pregnant rats. |
展开全文
相关产品
